Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial - The Lancet Infectious Diseases
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19
Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2 | Nature Communications
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
More adverse reactions following bivalent COVID-19 mRNA booster vaccine
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines
Bivalent mRNA booster effective, 'essential' for older adults
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination | NEJM
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study | The BMJ
Moderna on X: "A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after administration, and superiority
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
Am I Up to Date on My COVID Vaccinations? | Public Health Madison & Dane County
Vaccines | Free Full-Text | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
Three mRNA COVID-19 vaccine doses very effective in protecting against emergency department visits and hospitalizations associated with Omicron and Delta variants
CDC on X: "CDC recommends Novavax's non-mRNA booster for people ages 18+, for certain situations. This includes those unable or unwilling to receive mRNA #COVID19 vaccines. The Novavax COVID-19 booster targets the
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar | NEJM
How to choose a COVID-19 vaccine booster shot
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Data suggests mRNA booster dose generates stronger antibody response after J&J shot - Axios | Reuters
